Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents

The interaction between tumor surface-expressed PDL1 and immune cell PD1 for the evasion of antitumor immunity is well established and is targeted by FDA-approved anti-PDL1 and anti-PD1 antibodies. Nonetheless, recent studies highlight the immunopathogenicity of tumor-intrinsic PDL1 signals that can...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, Clare, Galvan, Eva, Ontiveros, Carlos, Deng, Yilun, Bai, Haiyan, Padron, Alvaro Souto, Hinchee-Rodriguez, Kathryn, Garcia, Myrna G., Kornepati, Anand, Conejo-Garcia, Jose, Curiel, Tyler J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099860/
https://www.ncbi.nlm.nih.gov/pubmed/35563520
http://dx.doi.org/10.3390/ijms23095129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099860/
https://www.ncbi.nlm.nih.gov/pubmed/35563520
http://dx.doi.org/10.3390/ijms23095129

Ejemplares similares